Optimizerx CORP (OPRX) — SEC Filings

Latest SEC filings for Optimizerx CORP. Recent 10-Q filing on Nov 7, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Optimizerx CORP on SEC EDGAR

Overview

Optimizerx CORP (OPRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: OptimizeRx Corp (OPRX) reported a significant turnaround in its financial performance for the three and nine months ended September 30, 2025. Net revenue for the three months increased by 22.3% to $26.067 million from $21.309 million in the prior year, while net revenue for the nine months rose by 2

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 5 bullish, 32 neutral, 2 mixed. The dominant filing sentiment for Optimizerx CORP is neutral.

Filing Type Overview

Optimizerx CORP (OPRX) has filed 6 10-Q, 20 8-K, 1 DEF 14A, 2 10-K, 1 DEFA14A, 5 SC 13G/A, 3 SC 13G, 1 8-K/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (39)

Risk Profile

Risk Assessment: Of OPRX's 29 recent filings, 0 were flagged as high-risk, 14 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Optimizerx CORP's most recent 10-Q filing (Nov 7, 2025):

Key Executives

Industry Context

OptimizeRx operates in the digital health and pharmaceutical marketing technology sector, a rapidly evolving space focused on improving patient access to medications and enhancing communication between manufacturers, providers, and patients. The industry is characterized by increasing adoption of data-driven solutions to streamline patient journeys and demonstrate value to stakeholders. Key trends include the integration of real-world data, personalized patient engagement, and the demand for measurable outcomes.

Top Tags

10-Q (5) · acquisition (5) · financial-reporting (4) · financials (4) · SEC Filing (3) · management-change (3) · compensation (3) · governance (3) · 8-k (3) · corporate-governance (3)

Key Numbers

Frequently Asked Questions

What are the latest SEC filings for Optimizerx CORP (OPRX)?

Optimizerx CORP has 39 recent SEC filings from Jan 2024 to Nov 2025, including 20 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of OPRX filings?

Across 39 filings, the sentiment breakdown is: 5 bullish, 32 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Optimizerx CORP SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Optimizerx CORP (OPRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Optimizerx CORP?

Key financial highlights from Optimizerx CORP's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for OPRX?

The investment thesis for OPRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Optimizerx CORP?

Key executives identified across Optimizerx CORP's filings include Chief Executive Officer, Dr. David J. Shulkin, Mr. David R. Glickman, Michael A. DeSimone, Jonathan M. Cohen and 1 others.

What are the main risk factors for Optimizerx CORP stock?

Of OPRX's 29 assessed filings, 0 were flagged high-risk, 14 medium-risk, and 15 low-risk.

What are recent predictions and forward guidance from Optimizerx CORP?

Forward guidance and predictions for Optimizerx CORP are extracted from SEC filings as they are enriched.

View on Read The Filing